Prostate Cancer最新文献_第7页

Prostate cancer in South Africa: pathology based national cancer registry data (1986-2006) and mortality rates (1997-2009). 南非前列腺癌:基于病理学的国家癌症登记数据(1986-2006年)和死亡率(1997-2009年)。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-05-15 DOI: 10.1155/2014/419801

Chantal Babb, Margaret Urban, Danuta Kielkowski, Patricia Kellett

{"title":"Prostate cancer in South Africa: pathology based national cancer registry data (1986-2006) and mortality rates (1997-2009).","authors":"Chantal Babb, Margaret Urban, Danuta Kielkowski, Patricia Kellett","doi":"10.1155/2014/419801","DOIUrl":"https://doi.org/10.1155/2014/419801","url":null,"abstract":"Prostate cancer is one of the most common male cancers globally; however little is known about prostate cancer in Africa. Incidence data for prostate cancer in South Africa (SA) from the pathology based National Cancer Registry (1986-2006) and data on mortality (1997-2009) from Statistics SA were analysed. World standard population denominators were used to calculate age specific incidence and mortality rates (ASIR and ASMR) using the direct method. Prostate cancer was the most common male cancer in all SA population groups (excluding basal cell carcinoma). There are large disparities in the ASIR between black, white, coloured, and Asian/Indian populations: 19, 65, 46, and 19 per 100 000, respectively, and ASMR was 11, 7, 52, and 6 per 100 000, respectively. Prostate cancer was the second leading cause of cancer death, accounting for around 13% of male deaths from a cancer. The average age at diagnosis was 68 years and 74 years at death. For SA the ASIR increased from 16.8 in 1986 to 30.8 in 2006, while the ASMR increased from 12.3 in 1997 to 16.7 in 2009. There has been a steady increase of incidence and mortality from prostate cancer in SA. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"419801"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/419801","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32447486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Robotic radical prostatectomy in patients with previous prostate surgery and radiotherapy. 机器人根治性前列腺切除术在既往前列腺手术和放疗患者中的应用。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-07-09 DOI: 10.1155/2014/367675

Omer Acar, Tarık Esen

{"title":"Robotic radical prostatectomy in patients with previous prostate surgery and radiotherapy.","authors":"Omer Acar, Tarık Esen","doi":"10.1155/2014/367675","DOIUrl":"https://doi.org/10.1155/2014/367675","url":null,"abstract":"Herein, we will review the available literature about robot-assisted radical prostatectomy in patients who have undergone prostate surgery or radiotherapy. Current data about this topic consists of small case series with limited follow-up. Despite being technically demanding, robot-assisted radical prostatectomy (RARP) can be considered feasible in either setting. Prostate surgery or prostatic irradiation should not be considered as a contraindication for robot-assisted radical prostatectomy. Nevertheless, patient counseling about the possible complications and the need for reintervention is of extreme importance in this patient population. Early oncologic and functional results of RARP performed in case of radiorecurrent prostate cancer look promising. Regarding postprostate surgery RARP, some series have reported comparable results, while some have demonstrated more inferior outcomes than those of naive cases. In order to assess the exact functional and oncologic outcome of RARP in patients with previous prostate surgery and radiotherapy, studies enrolling higher number of patients and providing longer follow-up data are needed. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"367675"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/367675","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32583318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer. CHEK2 (∗) 1100delC 突变与前列腺癌风险。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-11-06 DOI: 10.1155/2014/294575

Victoria Hale, Maren Weischer, Jong Y Park

引用次数: 0

Urodynamic evaluation after high-intensity focused ultrasound for patients with prostate cancer. 前列腺癌患者高强度聚焦超声后尿动力学评价。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-05-15 DOI: 10.1155/2014/462153

Luigi Mearini, Elisabetta Nunzi, Silvia Giovannozzi, Luca Lepri, Carolina Lolli, Antonella Giannantoni

{"title":"Urodynamic evaluation after high-intensity focused ultrasound for patients with prostate cancer.","authors":"Luigi Mearini, Elisabetta Nunzi, Silvia Giovannozzi, Luca Lepri, Carolina Lolli, Antonella Giannantoni","doi":"10.1155/2014/462153","DOIUrl":"https://doi.org/10.1155/2014/462153","url":null,"abstract":"This prospective study assesses the impact of high-intensity focused ultrasound (HIFU) on lower urinary tract by comparing pre- and postoperative symptoms and urodynamic changes. Thirty consecutive patients with clinically organ-confined prostate cancer underwent urodynamic study before HIFU and then at 3-6 months after surgery. Continence status and symptoms were analyzed by means of International Prostate Symptoms Score IPSS and International Index Erectile Function IIEF5. As a result, there were a significant improvement in bladder outlet, maximum flow at uroflowmetry, and reduction in postvoid residual PVR at 6-month follow-up and a concomitant significant reduction of detrusor pressure at opening and at maximum flow. De novo overactive bladder and impaired bladder compliance were detected in 10% of patients at 3 months, with progressive improvement at longer follow-up. Baseline prostate volume and length of the procedure were predictors of 6-month IPSS score and continence status. In conclusion, following HIFU detrusor overactivity, decreased bladder compliance and urge incontinence represent de novo dysfunction due to prostate and bladder neck injury during surgery. However, urodynamic study shows a progressive improvement in all storage and voiding patterns at 6-month follow-up. Patients with high prostate volume and long procedure length suffered from irritative symptoms even at long term. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"462153"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/462153","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32447487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Robotic Prostatectomy Has a Superior Outcome in Larger Prostates and PSA Density Is a Strong Predictor of Biochemical Recurrence. 机器人前列腺切除术在较大的前列腺中有更好的结果，PSA密度是生化复发的一个强有力的预测指标。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-12-15 DOI: 10.1155/2014/763863

S Bishara, N Vasdev, T Lane, G Boustead, J Adshead

{"title":"Robotic Prostatectomy Has a Superior Outcome in Larger Prostates and PSA Density Is a Strong Predictor of Biochemical Recurrence.","authors":"S Bishara, N Vasdev, T Lane, G Boustead, J Adshead","doi":"10.1155/2014/763863","DOIUrl":"https://doi.org/10.1155/2014/763863","url":null,"abstract":"Objectives. The aims of this study were to compare the outcomes of robotic assisted laparoscopic prostatectomy (RALP) between patients who had larger (≥75 g) and smaller (<75 g) prostates and to evaluate the performance of PSA density (PSAD) in determining the oncological outcome of surgery. Methods and Materials. 344 patients who underwent RALP at a single institution were included in the study. Preoperative risk factors and postoperative, oncological outcomes, erectile function, and continence status were recorded prospectively. Results. During a mean follow-up of 20 months, biochemical recurrence (PSA > 0.2) was observed in 15 patients (4.3%). Prostate size ≥75 g was associated with lower Gleason score on final pathology (P = 0.004) and lower pathological stage (P = 0.02) but an increased length of hospital stay (P = 0.05). PSAD on binary logistic regression independently predicted biochemical recurrence (BCR) when defined as postoperative PSA >0.1 (P = 0.001) and PSA >0.2 (P = 0.039). In both instances PSA was no longer a significant independent predictor. Conclusions. RALP in large prostates (≥75 g, <150 g) is as safe as RALP in smaller prostates and is associated with a lower pathological grade and stage. Higher PSAD is independently associated with BCR and is superior to PSA as a predictor of BCR after RALP. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"763863"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/763863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32968920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy? 他汀类药物或ASA是否影响前列腺癌外束放射治疗的生存率?

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-03-03 DOI: 10.1155/2014/184297

J Caon, M Paquette, J Hamm, T Pickles

{"title":"Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?","authors":"J Caon, M Paquette, J Hamm, T Pickles","doi":"10.1155/2014/184297","DOIUrl":"https://doi.org/10.1155/2014/184297","url":null,"abstract":"Background. Prior studies evaluating the effect of statins or acetylsalicylic acid (ASA) on the survival of men receiving prostate cancer were treatment have reported conflicting results, and have not adjusted for comorbidity. Our aim is to investigate the influence of statins and ASA on prostate cancer survival, when comorbidity is adjusted for, in men treated with external beam radiation therapy (EBRT) for prostate cancer. Methods. A cohort of 3851 patients with prostate cancer treated with curative EBRT ± androgen deprivation therapy (ADT) between 2000 and 2007. Stage, treatment, medication use, and Charlson comorbidity index (CCI) scores were analyzed. Results. Median followup was 8.4 years. Mean age was 70.3 years. Neoadjuvant ADT was used in 67%. Statins were used in 23%, ASA in 24%, and both in 11%. Comorbidity scores were 0 in 65%, 1 in 25%, and ≥2 in 10% of patients. Statin and ASA use were associated with increased age and comorbidity. Although statin and ASA use were significantly associated with improved prostate cancer specific survival (PCSS) on univariate analysis, neither were on multivariate analysis. Conclusion. Neither statin nor ASA use impacted PCSS on multivariate competing risks analysis. Survival was impacted by increased comorbidity as well as statin and ASA use. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"184297"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/184297","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32261671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29

Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. p73二核苷酸多态性在前列腺癌和p73蛋白异构体平衡中的作用。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-07-06 DOI: 10.1155/2014/129582

L Michael Carastro, Hui-Yi Lin, Hyun Y Park, Donghwa Kim, Selina Radlein, Kaia K Hampton, Ardeshir Hakam, Babu Zachariah, Julio Pow-Sang, Jong Y Park

{"title":"Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance.","authors":"L Michael Carastro, Hui-Yi Lin, Hyun Y Park, Donghwa Kim, Selina Radlein, Kaia K Hampton, Ardeshir Hakam, Babu Zachariah, Julio Pow-Sang, Jong Y Park","doi":"10.1155/2014/129582","DOIUrl":"https://doi.org/10.1155/2014/129582","url":null,"abstract":"Background. Molecular markers for prostate cancer (PCa) risks are currently lacking. Here we address the potential association of a dinucleotide polymorphism (DNP) in exon 2 of the p73 gene with PCa risk/progression and discern any disruption of p73 protein isoforms levels in cells harboring a p73 DNP allele. Methods. We investigated the association between p73 DNP genotype and PCa risk/aggressiveness and survival by fitting logistic regression models in 1,292 incident cases and 682 controls. Results. Although we detected no association between p73 DNP and PCa risk, a significant inverse relationship between p73 DNP and PCa aggressiveness (AT/AT + GC/AT versus GC/GC, OR = 0.55, 95%Cl = 0.31-0.99) was detected. Also, p73 DNP is marginally associated with overall death (dominant model, HR = 0.76, 95%Cl = 0.57-1.00, P = 0.053) as well as PCa specific death (HR = 0.69, 95%Cl = 0.45-1.06, P = 0.09). Western blot analyses for p73 protein isoforms indicate that cells heterozygous for the p73 DNP have lower levels of ∆Np73 relative to TAp73 (P < 0.001). Conclusions. Our findings are consistent with an association between p73 DNP and low risk for PCa aggressiveness by increasing the expressed TAp73/∆Np73 protein isoform ratio. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"129582"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/129582","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32564418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. 前列腺癌雄激素剥夺治疗后肥胖和体重增加的几率。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-04-22 DOI: 10.1155/2014/230812

Lior Z Braunstein, Ming-Hui Chen, Marian Loffredo, Philip W Kantoff, Anthony V D'Amico

{"title":"Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer.","authors":"Lior Z Braunstein, Ming-Hui Chen, Marian Loffredo, Philip W Kantoff, Anthony V D'Amico","doi":"10.1155/2014/230812","DOIUrl":"https://doi.org/10.1155/2014/230812","url":null,"abstract":"Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain of ≥10 lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received was associated with this endpoint adjusting for known prognostic factors. Results. By the 6-month followup, 12 men gained ≥10 lbs, of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared to RT + ADT were less likely to gain ≥10 lbs (adjusted odds ratio (AOR): 0.18 [95% CI: 0.04-0.89]; P = 0.04), whereas this risk increased with increasing BMI (AOR: 1.15 [95% CI: 1.01-1.31]; P = 0.04). Conclusions. Consideration should be given to avoid ADT in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened life expectancy from weight gain is expected. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"230812"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/230812","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32373102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial. 一项前瞻性随机试验的数据表明，预防肥胖措施可能改善前列腺癌的预后。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-02-13 DOI: 10.1155/2014/478983

Ravi A Chandra, Ming-Hui Chen, Danjie Zhang, Marian Loffredo, Anthony V D'Amico

{"title":"Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial.","authors":"Ravi A Chandra, Ming-Hui Chen, Danjie Zhang, Marian Loffredo, Anthony V D'Amico","doi":"10.1155/2014/478983","DOIUrl":"https://doi.org/10.1155/2014/478983","url":null,"abstract":"Purpose. Increasing body mass index (BMI) is associated with higher risk prostate cancer (PC) at presentation. Whether increasing BMI also prompts earlier salvage androgen suppression therapy (sAST) is unknown. Materials and Methods. Between 1995 and 2001, 206 men with unfavorable risk PC were treated with radiation therapy (RT) or RT and six months of androgen suppression therapy in a randomized controlled trial (RCT). 108 sustained PSA failure; 51 received sAST for PSA approaching 10 ng/mL; 49 with BMI data comprised the study cohort. A multivariable Cox regression analysis identified pretreatment factors associated with earlier sAST receipt. Results. Increasing BMI prompted earlier sAST (median years: 3.7 for overweight/obese, 6.9 for normal weight; adjusted hazard ratio (AHR): 1.11; 95% CI: 1.04, 1.18; P = 0.002) as did high versus other risk PC (median: 3.2 versus 5.2 years; AHR: 2.01; 95% CI: 1.05, 3.83; P = 0.03). Increasing median time to sAST was observed for overweight/obese men with high versus other risk PC and for normal-weight men with any risk PC being 2.3, 4.6, and 6.9 years, respectively (P < 0.001 for trend). Conclusion. Increasing BMI was associated with earlier sAST. A RCT evaluating whether BMI reduction delays or eliminates need for sAST is warranted. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"478983"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/478983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32228858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

DWI of Prostate Cancer: Optimal b-Value in Clinical Practice. 前列腺癌DWI:临床最佳b值。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-02-18 DOI: 10.1155/2014/868269

Guglielmo Manenti, Marco Nezzo, Fabrizio Chegai, Erald Vasili, Elena Bonanno, Giovanni Simonetti

{"title":"DWI of Prostate Cancer: Optimal b-Value in Clinical Practice.","authors":"Guglielmo Manenti, Marco Nezzo, Fabrizio Chegai, Erald Vasili, Elena Bonanno, Giovanni Simonetti","doi":"10.1155/2014/868269","DOIUrl":"https://doi.org/10.1155/2014/868269","url":null,"abstract":"Aim. To compare the diagnostic performance of diffusion weighted imaging (DWI) using b-values of 1000 s/mm(2) and 2000 s/mm(2) at 3 Tesla (T) for the evaluation of clinically significant prostate cancer. Matherials and Methods. Seventy-eight prostate cancer patients underwent a 3T MRI scan followed by radical prostatectomy. DWI was performed using b-values of 0, 1000, and 2000 s/mm(2) and qualitatively analysed by two radiologists. ADC maps were obtained at b-values of 1000 and 2000 s/mm(2) and quantitatively analyzed in consensus. Results. For diagnosis of 78 prostate cancers the accuracy of DWI for the young reader was significantly greater at b = 2000 s/mm(2) for the peripheral zone (PZ) but not for the transitional zone (TZ). For the experienced reader, DWI did not show significant differences in accuracy between b-values of 1000 and 2000 s/mm(2). The quantitative analysis in the PZ and TZ was substantially superimposable between the two b-values, albeit with a higher accuracy with a b-value of 2000 s/mm(2). Conclusions. With a b-value of 2000 s/mm(2) at 3T both readers differentiated clinical significant cancer from benign tissue; higher b-values can be helpful for the less experienced readers. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"868269"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/868269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32228860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29